BioProcess Technology Consultants, Inc. Hires Carol Kinoshita as Consultant

BioProcess Technology Consultants, Inc. Hires Carol Kinoshita as Consultant

 

WOBURN, MASSACHUSETTS, June 4, 2013 — BioProcess Technology Consultants (BPTC®), the leading strategic, technical, and regulatory consulting company for the global biopharmaceutical industry, has appointed Carol M. Kinoshita, Ph.D., to the position of Consultant.
"Carol brings an extensive background in the discovery and development of biopharmaceutical products, especially glycoproteins," said Susan Dana Jones, Ph.D., Vice President of BPTC®. "With specific glycoforms playing an increasingly significant role in the development of novel therapeutics, we are particularly delighted to have Carol join our team. Her experience and knowledge in downstream process development, manufacturing, and regulatory filings offer our clients additional expert support in these areas."

Dr. Kinoshita was most recently Associate Director of Process Development at Ipsen/Biomeasure, Inc., where she managed the late-stage process development for a therapeutic glycoprotein product and also led the development and research efforts for other product candidates. Previously, she served as Group Leader of Purification Process Development at TKT/Shire HGT, where she managed research and development, technology transfer, and manufacturing support for several key glycoprotein therapeutics, including Replagal and Vpriv.

She received her B.S. and M.S. from the University of Hawaii and her Ph.D. from the University of Wisconsin, Madison.

About BioProcess Technology Consultants

Founded in 1994, BPTC® is the recognized worldwide leader in biologics CMC consulting, providing a full range of technical, regulatory, and strategic assistance to biopharmaceutical and biotechnology companies in the development and commercialization of biopharmaceutical products. The company works with clients to find solutions to the challenges of producing biopharmaceutical supply from clone to commercial®. BPTC® helps clients develop manufacturing processes and strategies and assists in establishing product discovery and process development programs that enhance the overall value of client companies. BPTC® also helps investors make informed decisions by providing technical and business evaluations of new products and technologies and product discovery, development, and commercialization plans of potential investments and existing portfolio companies. For more information about BPTC®, visit BPTC.com and follow the Company on Twitter at bptcGlobal or LinkedIn at http://www.linkedin.com/company/bioprocess-technology-consultants-inc.

Suggested Articles

The deal, which features an additional $2 billion in milestones, will give Bayer control of an AAV platform and a clinical-phase pipeline.

The result, which beats the 35% reported by KRAS rival Amgen, sets Mirati up to file for FDA approval of the drug in the second half of next year.

Scorpion is working on precision oncology 2.0, including making better drugs for known targets, hitting undruggable targets and discovering new ones.